Popular Articles

Scientists Counteract Nanoparticle Lung Damage In Mice
Scientists have identified for the first time a mechanism by which nanoparticles cause lung damage and have demonstrated that it can be combated by blocking the process involved, taking a step toward addressing the growing concerns over the safety of nanotechnology.
new payday loan lenders
Novel Mechanism Controlling Tumor Growth In The Brain Revealed By Scripps Research Scientists
As survival rates among some patients with cancer continue to rise, so does the spread of these cancers to the brain - as much as 40 percent of all diagnosed brain cancers are considered metastatic, having spread from a primary cancer elsewhere in the body.
News of the day
Treatable Hormonal Condition Sometimes Overlooked In Infertility Patients
A condition known as congenital adrenal hyperplasia, or CAH, is easily treatable but frequently overlooked or misdiagnosed, leading to infertility and other "perplexing symptoms," the New York Times reports. CAH is a hormone deficiency that leads to excess production of androgens, which can hinder ovulation in women and cause low sperm count in men. It also can cause short stature, body odor, acne, irregular menstruation and excessive hair growth. The condition can be diagnosed through a blood test and treated with small doses of the steroid dexamethasone, which can reverse symptoms in three months to two-and-one-half years.According to Maria New, a leading authority on CAH and a professor of pediatrics and human genetics at Mount Sinai School of Medicine, the disease occurs in one in every 100 people in the general population. It is more common among certain ethnic groups, occurring in one in 27 Ashkenazi Jews and one in 40 Hispanics. Not everyone with the condition has symptoms or needs to be treated. The most severe form of the disease, classic CAH, can result in ambiguous genitalia in girls, while the milder nonclassical form sometimes produce no symptoms, the Times reports.Many fertility clinics do not test for the disease or only test after attempting other treatments. Some obstetricians are unaware of CAH and its effect on fertility, according to Zev Rosenwaks, director of the Center for Reproductive Medicine at New York Presbyterian-Weill Cornell hospital. CAH also can be confused with polycystic ovarian syndrome -- which has some similar symptoms -- or early puberty in younger patients (Tarkan, New York Times, 7/7).
Endocrinology

GenWay Biotech Obtains CLIA Certification

GenWay Biotech, Inc., a US-based diagnostic company has become CLIA certified and received a California lab license. Their license currently permits the testing of immunological biomarkers. This is a very important step in the direction of commercialization of the novel innovative diagnostic tests currently being developed at GenWay. In upcoming weeks, GenWay will add new cancer biomarker tests to their portfolio as well as several infectious diseases such as sexual transmitted diseases. GenWay is seeking to obtain CAP accreditation by the end of the year. Dr. Joe Voland, CLIA Pathologist and lab director, claims that he has never seen a CLIA lab get set up so efficiently and professionally as GenWay has done. GenWay Biotech Inc. is a GMP compliant facility with capabilities for research, development and manufacturing of proteins, antibodies, immunoassays, and diagnostics. Consequently, most quality control and assurance measures were already in place facilitating the transition into a CLIA certified laboratory. Furthermore, GenWay"s lab is under construction for the addition of a Class 10,000 clean room which should be complete sometime in August 2009. Dylan Malayter, Project Manager, who has played a predominant role in guiding the lab through the CLIA certification process, feels "This is an immense step forward for GenWay Biotech, Inc. We are excited to begin accepting patient samples and performing revolutionary tests that may save patients lives and enhance their treatment by monitoring their condition with simple non-invasive blood tests." The GenWay team is looking forward to the future impact of the cancer biomarker tests they will offer. They have secured exclusive rights to the DR-70 test from AMDL and have secured several other biomarkers in the field of cancer diagnostics. Dr. Jill Dombrauckas GenWay Biotech


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):